CClinicalTrials.gg
WithdrawnNCT04513613Updated Apr 23, 2021

ACHIEVE GRX Registry

An observational study in Peripheral Arterial Disease, Peripheral Vascular Diseases and Renal Artery Disease, sponsored by Corindus Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-23.

Sponsored by Corindus Inc. · Observational

Why this study was withdrawn
Sites have adjusted their participation priorities due to the pandemic. Not enough site interest at this current time to initiate the study.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate real-world performance of the CorPath GRX System in peripheral vascular interventions.

Read the detailed description

This is a prospective, single-arm, open-label, multi-center registry of the CorPath GRX System to evaluate its real-world performance during peripheral vascular interventions.

02

Conditions studied

  • Peripheral Arterial Disease
  • Peripheral Vascular Diseases
  • Renal Artery Disease
  • Carotid Artery Diseases
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with a clinical indication for Peripheral Vascular Intervention (PVI).

Inclusion criteria

  1. Age ≥ 18 years.
  2. Subject has a clinical indication for Peripheral Vascular Intervention (PVI).
  3. Subject is deemed appropriate for robotic-assisted PVI.
  4. The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.
  5. Individual monitoring of radiation dose, using the pocket dosimeter, was initiated at start of procedure.

Exclusion criteria

Exclusion Criteria:

  1. Failure/inability/unwillingness to provide informed consent.
  2. The investigator determines the subject or the peripheral anatomy is not suitable for ro-botic-assisted PVI.
  3. Women who are pregnant.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Subjects with a clinical indication for PVI

    Subjects with a clinical indication for Peripheral Vascular Intervention (PVI).

    Device: Procedure/Surgery: Robotic-PVI

Interventions

  • DeviceProcedure/Surgery: Robotic-PVI

    Robotic-assisted (CorPath GRX System) percutaneous vascular interventions.

05

What researchers measure

Primary outcomes

  1. Technical Success

    Successful completion of the robotic-assisted endovascular procedure absent any unplanned conversion to manual for guidewire or balloon/stent catheter inability to navigate vessel anatomy.

    Time frame: Procedure

  2. Clinical Success

    \<30% residual stenosis in all CorPath System treated lesions at the completion of the interventional procedure in the absence of device-related serious adverse event (SAE).

    Time frame: Within 24 hours of the procedure or hospital discharge, whichever occurs first.

  3. Safety

    A composite of intra- and peri-procedural events, including target vessel rupture, clinically significant perforation or dissection, and distal embolization.

    Time frame: Within 24 hours of the procedure or hospital discharge, whichever occurs first.

Secondary outcomes

  1. PVI Procedure Time

    Defined as the time measured from the insertion of the guiding sheath until the removal of the guiding sheath.

    Time frame: Procedure

  2. Manual Time

    Defined as the total amount of time the procedure is completed using a manual technique.

    Time frame: Procedure

  3. Robotic Time

    Defined as the total amount of time the procedure is completed robotically from the robotic cock-pit.

    Time frame: Procedure

  4. Fluoroscopy Time

    Total fluoroscopy utilized during the procedure as recorded by an Imaging System.

    Time frame: Procedure

  5. Operator Radiation Exposure

    Cumulative dose the operator receives as recorded from an electronic pocket dosimeter during the procedure.

    Time frame: Procedure

  6. Staff Radiation Exposure

    Cumulative dose the staff receives as recorded from an electronic pocket dosimeter during the procedure.

    Time frame: Procedure

  7. Patient Radiation Exposure

    DAP (dose-area-product) and AK (air kerma) as recorded during the procedure.

    Time frame: Procedure

  8. Contrast Fluid Volume

    Total volume of contrast (mL) used during the procedure.

    Time frame: Procedure

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • van Dijk LJ, van Noord D, de Vries AC, Kolkman JJ, Geelkerken RH, Verhagen HJ, Moelker A, Bruno MJ. Clinical management of chronic mesenteric ischemia. United European Gastroenterol J. 2019 Mar;7(2):179-188. doi: 10.1177/2050640618817698. Epub 2018 Dec 4. PubMed 31080602 ↗
  • Uccioli L, Meloni M, Izzo V, Giurato L, Merolla S, Gandini R. Critical limb ischemia: current challenges and future prospects. Vasc Health Risk Manag. 2018 Apr 26;14:63-74. doi: 10.2147/VHRM.S125065. eCollection 2018. PubMed 29731636 ↗
  • Dalal PK, Prasad A. Contemporary Outcomes of Endovascular Intervention for Critical Limb Ischemia. Interv Cardiol Clin. 2017 Apr;6(2):251-259. doi: 10.1016/j.iccl.2016.12.008. Epub 2017 Jan 27. PubMed 28257772 ↗
  • Canfield J, Totary-Jain H. 40 Years of Percutaneous Coronary Intervention: History and Future Directions. J Pers Med. 2018 Oct 1;8(4):33. doi: 10.3390/jpm8040033. PubMed 30275411 ↗
  • Pirau L, Lui F. Vertebrobasilar Insufficiency. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK482259/ PubMed 29489229 ↗
  • Schoepe R, McQuillan S, Valsan D, Teehan G. Atherosclerotic Renal Artery Stenosis. Adv Exp Med Biol. 2017;956:209-213. doi: 10.1007/5584_2016_89. PubMed 27873231 ↗
  • Writing Committee Members; Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME; ACC/AHA Task Force Members; Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis J, Joglar J, Pressler SJ, Wijeysundera DN. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vasc Med. 2017 Jun;22(3):NP1-NP43. doi: 10.1177/1358863X17701592. No abstract available. PubMed 28494710 ↗
  • White RD, Weir-McCall JR, Sullivan CM, Mustafa SA, Yeap PM, Budak MJ, Sudarshan TA, Zealley IA. The celiac axis revisited: anatomic variants, pathologic features, and implications for modern endovascular management. Radiographics. 2015 May-Jun;35(3):879-98. doi: 10.1148/rg.2015140243. Epub 2015 Apr 17. PubMed 25884099 ↗
  • Beckman JA, Creager MA. Chapter 18 Peripheral Artery Disease Clinical Evaluation. In: Creager MA, Beckman JA, Loscalzo J, eds. Vascular Medicine: A Companion to Braunwald's Heart Disease. Philadelphia, PA: Elsevier Saunders; 2013
  • Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 Oct 19;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0. Epub 2013 Aug 1. PubMed 23915883 ↗
  • Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR, Criqui MH. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007 Apr;32(4):328-33. doi: 10.1016/j.amepre.2006.12.010. Erratum In: Am J Prev Med. 2014 Jul;47(1):103. PubMed 17383564 ↗
  • Klein LW, Miller DL, Balter S, Laskey W, Haines D, Norbash A, Mauro MA, Goldstein JA; Joint Inter-Society Task Force on Occupational Hazards in the Interventional Laboratory. Occupational health hazards in the interventional laboratory: time for a safer environment. Catheter Cardiovasc Interv. 2009 Feb 15;73(3):432-8. doi: 10.1002/ccd.21801. PubMed 19214981 ↗
  • Kim KP, Miller DL, Balter S, Kleinerman RA, Linet MS, Kwon D, Simon SL. Occupational radiation doses to operators performing cardiac catheterization procedures. Health Phys. 2008 Mar;94(3):211-27. doi: 10.1097/01.HP.0000290614.76386.35. PubMed 18301095 ↗
  • Vano E, Gonzalez L, Beneytez F, Moreno F. Lens injuries induced by occupational exposure in non-optimized interventional radiology laboratories. Br J Radiol. 1998 Jul;71(847):728-33. doi: 10.1259/bjr.71.847.9771383. PubMed 9771383 ↗
  • Goldsweig AM, Abbott JD, Aronow HD. Physician and Patient Radiation Exposure During Endovascular Procedures. Curr Treat Options Cardiovasc Med. 2017 Feb;19(2):10. doi: 10.1007/s11936-017-0507-9. PubMed 28275940 ↗
  • El-Sayed T, Patel AS, Cho JS, Kelly JA, Ludwinski FE, Saha P, Lyons OT, Smith A, Modarai B; Guy's and St Thomas' Cardiovascular Research Collaborative. Radiation-Induced DNA Damage in Operators Performing Endovascular Aortic Repair. Circulation. 2017 Dec 19;136(25):2406-2416. doi: 10.1161/CIRCULATIONAHA.117.029550. Epub 2017 Oct 20. PubMed 29054934 ↗
  • Goldsweig AM, Kennedy KF, Kolte D, Abbott JD, Gordon PC, Sharaf BL, Sellke FW, Ehsan A, Sodha NR, Rutar F, Aronow HD. Predictors of patient radiation exposure during transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2018 Oct 1;92(4):768-774. doi: 10.1002/ccd.27452. Epub 2017 Dec 27. PubMed 29280551 ↗
  • Mahmud E, Schmid F, Kalmar P, Deutschmann H, Hafner F, Rief P, Brodmann M. Feasibility and Safety of Robotic Peripheral Vascular Interventions: Results of the RAPID Trial. JACC Cardiovasc Interv. 2016 Oct 10;9(19):2058-2064. doi: 10.1016/j.jcin.2016.07.002. Epub 2016 Sep 14. PubMed 27639904 ↗
  • Vano E, Gonzalez L, Fernandez JM, Haskal ZJ. Eye lens exposure to radiation in interventional suites: caution is warranted. Radiology. 2008 Sep;248(3):945-53. doi: 10.1148/radiol.2482071800. Epub 2008 Jul 15. PubMed 18632529 ↗
  • Weisz G, Metzger DC, Caputo RP, Delgado JA, Marshall JJ, Vetrovec GW, Reisman M, Waksman R, Granada JF, Novack V, Moses JW, Carrozza JP. Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study. J Am Coll Cardiol. 2013 Apr 16;61(15):1596-600. doi: 10.1016/j.jacc.2012.12.045. PubMed 23500318 ↗
  • Smitson CC, Ang L, Pourdjabbar A, Reeves R, Patel M, Mahmud E. Safety and Feasibility of a Novel, Second-Generation Robotic-Assisted System for Percutaneous Coronary Intervention: First-in-Human Report. J Invasive Cardiol. 2018 Apr;30(4):152-156. Epub 2018 Jan 15. PubMed 29335386 ↗
  • Smilowitz NR, Moses JW, Sosa FA, Lerman B, Qureshi Y, Dalton KE, Privitera LT, Canone-Weber D, Singh V, Leon MB, Weisz G. Robotic-Enhanced PCI Compared to the Traditional Manual Approach. J Invasive Cardiol. 2014 Jul;26(7):318-21. PubMed 24993988 ↗
  • Mahmud E, Dominguez A, Bahadorani J. First-in-human robotic percutaneous coronary intervention for unprotected left main stenosis. Catheter Cardiovasc Interv. 2016 Oct;88(4):565-570. doi: 10.1002/ccd.26550. Epub 2016 May 18. PubMed 27189238 ↗

Study documents

  • Study protocol · Jul 28, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT04513613
Lead sponsor
Corindus Inc.
Responsible party
Sponsor
First posted
Aug 14, 2020
Start date
Jan 2022 (estimated)
Primary completion
Jan 2023 (estimated)
Completion
Jan 2023 (estimated)
Last update
Apr 23, 2021

Study contacts

Jon George, MD
principal investigator · Einstein Medical Center
John Phillips, MD
principal investigator · Riverside Methodist Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion